The Company has authorized share capital of an unlimited number of voting common shares and the shares do have a stated par value.

 

Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to vote per share at the Company's annual general meeting and any extraordinary general meeting.

 

 

During the months ended there were common shares issued directly or upon the exercise of any stock options or warrants.

 

 

On the Company completed, in tranches, a brokered and non-brokered private placement of units at a price of per unit for aggregate gross proceeds of approximately million. Each unit consisted of common share and half of common share purchase warrant. The Company issued warrants. Each warrant entitles the holder to purchase common share at a price of at any time prior to expiry on and for Tranche and Tranche respectively. The warrants are subject to early expiry under certain conditions. The warrant expiry date can be accelerated at the option of the Company, in the event that the volume-weighted average trading price of the Company’s common shares exceeds per common share for any consecutive trading days. In connection with this offering, the Company paid aggregate finder’s fees of approximately and issued an aggregate of compensation warrants. Each compensation warrant entitles the holder to purchase common share at for a period of years from the closing of the offering, subject to acceleration on the same terms as the common share purchase warrants.

 

 

Common shares reserved for future issuance are as follows:

		March 31, 2019
Stock options outstanding			674,045
Deferred share units outstanding			21,183
Shares available for grant under the DiaMedica Therapeutics Inc. Stock Option Plan			88,690
Common shares issuable under common share purchase warrants			807,563
Total			1,591,481